Eos/Pharmacopeia merger terminated
Executive Summary
Eos and Pharmacopeia will continue to jointly own all compounds developed from the December transfer of Eos' therapeutic antibody target AAB1 to Pharmacopeia following termination of merger plans (1"The Pink Sheet" Aug. 27, 2001, p. 28)...
You may also be interested in...
Pharmacopeia/Eos Plan To Outlicense First Therapeutic By 2005
Pharmacopeia plans to outlicense its first therapeutic candidate resulting from its merger with genomics firm Eos by 2005.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.